Regulatory–HTA divergence in rare disease outcome assessment: what early evidence planning can do

Open-Source Models in HEOR: Where Transparency Meets Efficiency

From Global to Local: Why Country Adaptations Matter

When “Immature” Doesn’t Mean “Unusable”: What NICE’s Oncology Decisions Reveal About OS Evidence

Immature Overall Survival Data in NICE Oncology Appraisals: Why It Matters for Decision-Making

From Model to Interface: A Case Study on Making Health Economics Accessible with R Shiny

From Model to Manuscript: Five Essential Strategies for Publishing Health Economic Models

The Who, When and How of Model Validation in Health Economics

Early models meet real world impact

Early economic analysis and embracing uncertainty

Market Access in the EU: Helping you prepare for upcoming regulatory changes

Early Evidence Generation: A Strategic Roadmap to Successful Market Access

The Power of Early Evidence in Market Access

Demonstrating value: Real-World Evidence (RWE) in IRA’s Medicare Drug Price Negotiation

Getting real: real-world evidence in healthcare

My summer internship at Symmetron

A cloud computing solution for improving the run-time of individual patient simulation models

Unmet medical need and market access: enabler or barrier to innovation?

What is qualitative evidence synthesis?

Market access: budget impact analysis

When is a simple model enough? How to handle structural uncertainty in cost-effectiveness models.

Health economic modelling: a guide for pharmaceutical and medical device companies

Evidence generation and communication in drug development

Market access for immuno-oncology (I-O) therapies in the UK

Evidence synthesis for healthcare decision-making